Targeting the issues in chronic obstructive lung disease

Bibliography

• CHERNIAK NS: Chronic Obstructive Pulmonary Disease. WB Saunders Company, Philadelphia (1991).
   Google Scholar
• •A classic discussion of the pathology of COPD.
   Google Scholar
• HODGKIN JE, CELLI BR., CONNORS GL (Eds): Pulmonary Rehabilitation; Guidelines to Success Ord ed). Lippincott Williams & Wilkins, Philadelphia (2000).
   Google Scholar
• NO AUTHORS LISTED: Morbidity &-Mortalig, .. 1998 Chart Book on Cardiovascular, Lung, and Blood Diseases. National Heart, Lung, and Blood Institute. (1998).
   Google Scholar
• BARNES PJ: Molecular genetics of chronic obstructive pulmonary disease. Thorax (1999) 54:245–252.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Medical progress: chronic obstructive pulmonary disease. N Engl. .1 Med. (2002) 343:269–280.
   Google Scholar
• ••An excellent review of progress to date inthe treatment of COPD.
   Google Scholar
• BARNES PJ: Future advances in COPD therapy. Respir. (2001) 68:441–448.
   PubMed Web of Science ®Google Scholar
• NIEWOEHNER DE, ERBLAND ML, DEUPREE RH et al.: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl. .1 Med. (1999) 340:1941–1947.
   Google Scholar
• DAVIES L, ANGUS RM, CALVERLEY PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet (1999) 354:456–460.
   PubMed Web of Science ®Google Scholar
• TRUITT T, WITKO J, HALPERN M: Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest (2003) 123:128–135.
   PubMed Web of Science ®Google Scholar
• VAN NOORD JA, SMEETS JJ, CUSTERS FLJ, KORDUCKI L, CORNELISSEN PJG: Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. (2002) 19:639–644.
   PubMed Web of Science ®Google Scholar
• NOGUERA A, BATLE S, MIRALLES C et al.: Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax (2001) 56:432–437.
   PubMed Web of Science ®Google Scholar
• STOCKLEY RA: Neutrophils and protease/ antiprotease imbalance. Am. Respir. Grit. Care Med. (1999) 160:S49–S52.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, BARNETTE MS, UNDERWOOD DC et al.: ArifloTM (0207499), a second-generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Palm. Pharmacol Ther. (1999) 12:131–135.
   PubMed Web of Science ®Google Scholar
• OHNISHI K, TAKAGI M, KUROKAWA Y, SATOMI S, KONTTINEN YT: Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. (1998) 78:1077–1087.
   PubMed Web of Science ®Google Scholar
• FORMAN HJ, TORRES M: Reactive oxygen species and cell signaling. Am. Respir. Crit. Care Med. (2002) 166:S4–S8.
   PubMed Web of Science ®Google Scholar
• MONTUSCHI P, COLLINS JV, CIABATTONI G et al.: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. .1 Respir. Grit. Care Med. (2000) 162:1175–1177.
   Google Scholar
• HOBBS AJ, HIGGS A, MONCADA S: Inhibition of nitric oxide synthase as a potential therapeutic target. Ann. Rev Pharmacol Toxicol (1999) 39:191–220.
   PubMed Web of Science ®Google Scholar
• YVONNE M, JANSSEN-HEININGER W, PERSINGER RL et al.: Reactive nitrogen species and cell signaling. Respir. Grit. Care Med. (2002) 166:S9–S16.
   PubMed Web of Science ®Google Scholar
• GRANDJEAN TM, BERTHET P, RUFFMANN R, LEUENBERGER P: Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double blind, placebo-controlled clinical trials. Clin. Ther. (2000) 22:209–221.
   PubMed Web of Science ®Google Scholar
• LUMIERE C, BECKER A, BOULET LP et al.: Should combination therapy with inhaled corticosteroids and long-acting [beta]2-agonists be prescribed as initial maintenance treatment for asthma? Can. Med. Assoc. (2002) 167:1008–1009.
   PubMed Web of Science ®Google Scholar
• IND P, HAUGHNEY J, PRICE D, ROSEN JP, KENNELLY J: Four month adjustable or fixed BD dosing with budesonide/formoterol in a single inhaler reduces symptom severity. Thorax (2002) (Suppl. 3):S142.
   Google Scholar
• HAUGHNEY J, PRICED, ROSEN JP, MORRISON K: Symbicort used in a guided self management plan provides additional enablement to asthma patients compared to fixed dosing. Thorax (2002) (Suppl. 3):S143.
   Google Scholar
• NELSON HS: Advair: combination treatment with fluticasone propionate/ salmeterol in the treatment of asthma. Allergy Clin. Immunol (2001) 107:397–416.
   Google Scholar
• ZUWALLACK RL, MAHLER DA, REILLY D et al.: Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest (2001) 119:1661–1670.
   PubMed Web of Science ®Google Scholar
• YOUNG A, DOUGALL I, JACKSON D et al.: ViozanTM, a novel dual D2-receptor and B2-adrenoceptor agonist, inhibits clinically relevant parameters in animal models of airways disease. Respir. Crit. Care Med. (2000) 161:A820.
   Google Scholar
• GIEMBYCZ MA: Cilomilast: a second-generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs(2001) 10: 1361–1379.
   Google Scholar
• ABRAHAM WM, AHMED A, SIELCZAK MW, NARITA M, ARRHENIUS T, ELICES MJ: Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. Am.Respir. Crit. Care Med. (1997)156:696–703.
   PubMed Web of Science ®Google Scholar
• TOKUHIRA M, HOSAKA S, VOLIN M et al.: Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum. (2000) 43:1122–1133.
   PubMed Web of Science ®Google Scholar